BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 637492)

  • 21. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunotherapy].
    Lejeune FJ; Bernheim JL; Vanwijck R
    Acta Chir Belg; 1974 Mar; 73(2):265-93. PubMed ID: 4450923
    [No Abstract]   [Full Text] [Related]  

  • 23. BCG in cancer therapy: theoretical bases of immunotherapy.
    Dodd MJ
    Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
    [No Abstract]   [Full Text] [Related]  

  • 24. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
    Seigler HF; Shingleton WW; Pickrell KL
    Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract]   [Full Text] [Related]  

  • 26. [Intralesion BCG vaccine therapy in cutaneous melanoma metastasis].
    Wolf M; Menzel W
    Dermatol Monatsschr; 1978 Sep; 164(9):671-2. PubMed ID: 710658
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunological changes in cancer patients receiving BCG.
    Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE
    Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intralesional BCG application in malignant melanoma.
    Sopková B; Kolár V
    Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological factors which influence response to immunotherapy in malignant melanoma.
    Morton D; Eilber FR; Malmgren RA; Wood WC
    Surgery; 1970 Jul; 68(1):158-63; discussion 163-4. PubMed ID: 10483463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N; Crowther D
    Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response.
    Ahn SS; Irie RF; Weisenburger TH; Jones PC; Juillard G; Roe DJ; Morton DL
    Surgery; 1982 Aug; 92(2):362-7. PubMed ID: 7101129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [BCG-treatment of malignant melanoma].
    Borberg H
    Internist (Berl); 1975 Oct; 16(10):482-5. PubMed ID: 1107254
    [No Abstract]   [Full Text] [Related]  

  • 33. HLA-B7 associated tuberculin hyporesponsiveness in BCG treated melanoma patients.
    Buckley CE; White DH; Seigler HF
    Monogr Allergy; 1977; 11():97-105. PubMed ID: 876133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunotherapy of malignant melanomas].
    Macher E
    Haematol Blood Transfus; 1978; 21():285-91. PubMed ID: 738638
    [No Abstract]   [Full Text] [Related]  

  • 35. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
    Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunoreactivity in patients with surgically removed melanoma in the course of BCG vaccination (author's transl)].
    Lochman I; Kyselá T; Machálek J; Lochmanová A; Beska F
    Cesk Dermatol; 1980; 55(6):372-7. PubMed ID: 7460040
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
    Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
    Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of malignant melanoma by intratumoral injection of BCG.
    Pinsky CM; Hirshaut Y; Oettgen HF
    Natl Cancer Inst Monogr; 1973 Dec; 39():225-8. PubMed ID: 4595322
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunotherapy and immune competence of patients with malignant melanoma.
    Kovarík J; Ninger E; Mechl Z; Zemanová D; Lauerová L; Sopková B; Svejda J; Bacovský B; Bártová A; Bártek J
    Czech Med; 1983; 6(3):172-4. PubMed ID: 6416794
    [No Abstract]   [Full Text] [Related]  

  • 40. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H; Kolarić K; Malenica B; Nola P
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.